Abstract:Background Sulpiride is a relatively old antipsychotic drug reputed to have low incidence of adverse effects and an effect on the negative symptoms of schizophrenia. This relatively inexpensive antipsychotic drug has a similar neuropharmacological profile to several novel atypical drugs. Objectives To evaluate the effects of sulpiride for schizophrenia and other similar serious mental illnesses in comparison with placebo. Search strategy We searched the Cochrane Schizophrenia Group Trials Register (September 2008) and references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information. Selection criteria We included all randomised controlled trials (RCTs) comparing sulpiride with placebo for people with schizophrenia and other types of schizophrenia-like psychoses. The primary outcome of interest was clinically significant response in global state. Data collection and analysis We independently inspected citations and abstracts, ordered papers, re-inspected and quality assessed these. IMO and JW extracted data. We analysed dichotomous data using random-effects relative risk (RR) and estimated the 95% confidence interval (CI) around this. Where continuous data were included, we analysed this data using random-effects weighted mean difference (WMD) with a 95% confidence interval. Main results Two trials of short duration compare sulpiride with placebo (total n=113). As regards mental state, there were no clear differences between groups for either positive or negative symptoms (n=18, 1 RCT, WMD Manchester scale negative subscore -0.30 CI -1.66 to 1.06; n=18, 1 RCT, WMD SANS 2.90 CI -0.14 to 5.94). Few people left these studies by three months (n=113, 2 RCTs, RR 1.00 CI 0.25 to 4.00). One subscore finding found sulpiride improved social behavior (n=18,1 RCT, WMD -2.90 CI -5.60 to -0.20). There were no data for many important outcomes such as general functioning, service use or adverse effects. Author's conclusions Sulpiride may be an effective antipsychotic drug but evidence of its superiority over placebo from randomised trials is very limited. Practice will have to use evidence from sources other than trials until better evidence is generated.

The antipsychotic agent sulpiride microinjected into the ventral pallidum restores positive symptom-like habituation disturbance in MAM-E17 schizophrenia model rats

Remediation of Attentional Dysfunction in Rats with Lesions of the Medial Prefrontal Cortex by Intra-Accumbens Administration of the Dopamine D(2/3) Receptor Antagonist Sulpiride.

Sulpiride Alleviates the Attentional Impairments of Rats with Medial Prefrontal Cortex Lesions

The D2-like Dopamine Receptor Agonist Quinpirole Microinjected Into the Ventral Pallidum Dose-Dependently Inhibits the VTA and Induces Place Aversion

Stimulatory Effect of the D2 Antagonist Sulpiride on Glucose Utilization in Dopaminergic Regions of Rat Brain

Impaired Set-Shifting and Dissociable Effects on Tests of Spatial Working Memory Following the Dopamine D2 Receptor Antagonist Sulpiride in Human Volunteers.

The modulatory role of accumbens and hippocampus D2 receptors in anxiety and memory

Sulpiride versus placebo for schizophrenia.

Effects of Dopamine D2/D3 Receptor Antagonism on Human Planning and Spatial Working Memory

The Dopamine D2 Receptor Antagonist Sulpiride Modulates Striatal BOLD Signal During the Manipulation of Information in Working Memory.

Acute Behavioral and Neurochemical Effects of Sulpiride in Adult Zebrafish

Dopaminergic mechanisms underlying the expression of antipsychotic-induced dopamine supersensitivity in rats

Systemic Sulpiride in Young Adult Volunteers Simulates the Profile of Cognitive Deficits in Parkinson’s Disease

Conjugation of sulpiride with a cell penetrating peptide to augment the antidepressant efficacy and reduce serum prolactin levels

Sulpiride Modulates Striatal Bold Signal During the Manipulation of Information in Working Memory

Effect of intrahippocampal microinjection of VU0155041, a positive allosteric modulator of mGluR4, on long term potentiation in a valproic acid-induced autistic male rat model

Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel Mglu5 Positive Allosteric Modulator.

Bilateral Intra-Accumbens Self-Administration of D-Amphetamine: Antagonism with Intra-Accumbens SCH-23390 and Sulpiride.

Optogenetic Inhibition of Ventral Hippocampal Neurons Alleviates Associative Motor Learning Dysfunction in a Rodent Model of Schizophrenia.

Amantadine enhances nigrostriatal and mesolimbic dopamine function in the rat brain in relation to motor and exploratory activity